This Cochrane systematic review pooled 22 trials (9,137 participants) to determine whether combining IPC with pharmacological prophylaxis prevents VTE better than either method alone. It addresses a core question in perioperative care: does dual-modality prophylaxis justify the added bleeding risk?
The central clinical question this review addresses is which modality to add when a high-risk surgical patient needs escalated VTE prophylaxis.
If your patient is already on IPC alone, adding anticoagulation reduces DVT but raises major bleeding risk approximately sevenfold (0.1% to 1.5%). That trade-off must be weighed explicitly, particularly in neurosurgical or trauma patients where bleeding consequences are severe.
If your patient is already on anticoagulation, adding IPC reduces PE risk by roughly 60% (OR 0.39) without adding any measurable bleeding risk. This asymmetry is the most actionable insight from this paper: IPC is the safer modality to layer on top of existing anticoagulation.
The review also confirms that no significant difference in benefit exists between orthopedic and non-orthopedic patients, supporting guideline recommendations for dual modalities across high-risk surgical populations generally.
The moderate-to-very-low GRADE ratings are a real limitation. Multiple primary findings lost significance in sensitivity analyses that excluded high-bias studies, meaning the magnitude of benefit is uncertain. Use these findings to support guideline-concordant practice, not to override individualized clinical judgment.
This Cochrane systematic review pooled 22 trials (9,137 participants) to determine whether combining IPC with pharmacological prophylaxis prevents VTE better than either method alone. It addresses a core question in perioperative care: does dual-modality prophylaxis justify the added bleeding risk?
The central clinical question this review addresses is which modality to add when a high-risk surgical patient needs escalated VTE prophylaxis.
If your patient is already on IPC alone, adding anticoagulation reduces DVT but raises major bleeding risk approximately sevenfold (0.1% to 1.5%). That trade-off must be weighed explicitly, particularly in neurosurgical or trauma patients where bleeding consequences are severe.
If your patient is already on anticoagulation, adding IPC reduces PE risk by roughly 60% (OR 0.39) without adding any measurable bleeding risk. This asymmetry is the most actionable insight from this paper: IPC is the safer modality to layer on top of existing anticoagulation.
The review also confirms that no significant difference in benefit exists between orthopedic and non-orthopedic patients, supporting guideline recommendations for dual modalities across high-risk surgical populations generally.
The moderate-to-very-low GRADE ratings are a real limitation. Multiple primary findings lost significance in sensitivity analyses that excluded high-bias studies, meaning the magnitude of benefit is uncertain. Use these findings to support guideline-concordant practice, not to override individualized clinical judgment.